Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – CNTB
In the Feb 19 session, CNTB declined 1.02%, reflecting a mild negative market reaction. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | MOA/data update | Positive | -1.4% | Highlighted new rademikibart mechanism data and outlined 2026 clinical priorities. |
| Nov 24 | Conference participation | Neutral | -4.3% | Announced fireside chat at the 8th Annual Evercore Healthcare Conference. |
| Nov 12 | Earnings update | Positive | +5.9% | Reported Q3 2025 results and business update with ongoing Phase 2 programs. |
| Sep 29 | Clinical data update | Positive | -16.6% | Presented Phase 2b rademikibart data with significant FEV1 gains and fewer exacerbations. |
| Sep 04 | Conference preview | Neutral | -10.6% | Announced two upcoming ERS 2025 poster presentations on rademikibart in asthma. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent scientific and mechanism-of-action updates often coincided with negative next-day moves, whereas the latest earnings and business update saw a positive reaction, suggesting mixed trading responses to news versus data-heavy disclosures.
Over the past six months, CNTB has focused on rademikibart and respiratory indications. Key events included ERS 2025 data showing lung-function gains and reduced exacerbations, multiple conference presentations, and a Q3 2025 update noting $54.8M in cash and expected runway into 2027. Several data and conference announcements saw negative next-day moves, while the November 2025 earnings and business update drew a positive reaction. Today’s Oppenheimer conference appearance fits the pattern of ongoing visibility efforts rather than a discrete clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26th, 2026 at 2:40 p.m. ET.
The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately
For more information visit www.connectbiopharma.com.
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
